Get started
Author

Joseph C. Del Paggio

Observed names: J C Del Paggio, J. Del Paggio, J.C. Del Paggio, Joseph C Del Paggio, Joseph Cosimo Del Paggio, Joseph Del Paggio
Observed institutions: University of Toronto, Queen's University, Thunder Bay Regional Health Sciences Centre, Princess Margaret Cancer Centre, Queens University, Canadian Cancer Trials Group, NOSM University
ORCID: 0000-0001-5281-2746
Observed ORCID: 0000-0001-5281-2746
OpenAlex ID: A5080696424
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology
2021 · Joseph C. Del Paggio, John S. Berry, et al. · JAMA Oncology · 229
PDF
An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries
2021 · J. Connor Wells, Shubham Sharma, et al. · JAMA Oncology · 183
PDF
Cancer immunotherapy and the value of cure
2018 · Joseph C. Del Paggio · Nature Reviews Clinical Oncology · 182
Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks
2017 · Joseph C Del Paggio, Richard Sullivan, et al. · The Lancet Oncology · 151
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
2017 · Ariadna Tibau, Consolación Molto, et al. · JNCI Journal of the National Cancer Institute · 90
PDF
Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
2016 · J.C. Del Paggio, B. Azariah, et al. · Annals of Oncology · 90
The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis
2019 · Joseph C Del Paggio, Ian F Tannock · The Lancet Oncology · 76
Five years of EMA-approved systemic cancer therapies for solid tumours—a comparison of two thresholds for meaningful clinical benefit
2017 · N. Grössmann, J.C. Del Paggio, et al. · European Journal of Cancer · 42
PDF
Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation
2021 · A. Fundytus, J.C. Wells, et al. · Clinical Oncology · 37
A mitochondrial redox oxygen sensor in the pulmonary vasculature and ductus arteriosus
2015 · Kimberly J. Dunham-Snary, Zhigang G. Hong, et al. · Pflügers Archiv - European Journal of Physiology · 36
Approvals in 2016: questioning the clinical benefit of anticancer therapies
2017 · Christopher M. Booth, Joseph C. Del Paggio · Nature Reviews Clinical Oncology · 34
Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials
2018 · Ariadna Tibau, Consolación Molto, et al. · JAMA Oncology · 33
PDF
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study
2024 · Joseph C Del Paggio, Rohini Naipaul, et al. · The Lancet Oncology · 27
Population-based study to re-evaluate optimal lymph node yield in colonic cancer
2017 · J C Del Paggio, Y Peng, et al. · British journal of surgery · 25
Lymph Node Evaluation for Colon Cancer in Routine Clinical Practice: A Population-Based Study
2017 · J.C. Del Paggio, S. Nanji, et al. · Current Oncology · 17
PDF
Re-aligning the ASCO and ESMO clinical benefit frameworks for modern cancer therapies
2017 · J.C. Del Paggio, R. Sullivan, et al. · Annals of Oncology · 10
Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups
2018 · Joseph C Del Paggio, Sierra Cheng, et al. · JNCI Cancer Spectrum · 8
PDF
Addressing the quality of the ESMO-MCBS
2017 · J.C. Del Paggio · Annals of Oncology · 8
PDF
Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved
2025 · Charlotte Ouimet, Bianca Fodor, et al. · JNCI Journal of the National Cancer Institute · 7
Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies
2023 · Nora Hutchinson, Selin Bicer, et al. · JCO Oncology Practice · 6
Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials
2023 · Hannah Moyer, Merlin Bittlinger, et al. · Journal of Clinical Epidemiology · 6
Acute generalized exanthematous pustulosis with multisystem manifestations
2017 · Allison Rosen, Joseph C. Del Paggio, et al. · Annals of Allergy Asthma & Immunology · 6
A critique of the fragility index – Authors' reply
2019 · Joseph C Del Paggio, Ian F Tannock · The Lancet Oncology · 5
Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity
2022 · J. Connor Wells, Adam Fundytus, et al. · Current Oncology · 4
PDF
Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity—Reply
2021 · Joseph C. Del Paggio, Elizabeth A. Eisenhauer, et al. · JAMA Oncology · 4
Works count: 46
Citation count: 1,349
H-index: 15
I10-index: 16
Year
Topic
Type